Pfizer begins mid-stage trial for new vaccine targeting Omicron subvariant – National
Pfizer Inc and its German accomplice BioNTech SE mentioned on Wednesday that they had began a mid-stage research of a modified COVID-19 vaccine which targets each the unique in addition to the BA.2 Omicron subvariant.
Pfizer mentioned the vaccine is in an preliminary proof-of-concept research to collect extra information.
Learn extra:
COVID vaccination clinics to be held at Caribbean Carnival, different summer time occasions in Toronto
Collectively, the BA.4 and BA.5 subvariants are estimated to make up practically 95% of the circulating coronavirus variants in america for the week ended July 23.
The U.S. Meals and Drug Administration final month requested vaccine producers to focus on BA.4 and BA.5, the 2 at present dominant Omicron subvariants, for a possible fall season booster dose.
